for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catalent Inc

CTLT.N

Latest Trade

87.80USD

Change

2.90(+3.42%)

Volume

171,177

Today's Range

85.18

 - 

88.16

52 Week Range

31.07

 - 

91.18

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
84.90
Open
85.68
Volume
171,177
3M AVG Volume
31.00
Today's High
88.16
Today's Low
85.18
52 Week High
91.18
52 Week Low
31.07
Shares Out (MIL)
162.77
Market Cap (MIL)
13,819.14
Forward P/E
47.52
Dividend (Yield %)
--

Next Event

Q4 2020 Catalent Inc Earnings Call

Latest Developments

More

Catalent Sees FY 2020 Revenue $3.084 Billion To $3.096 Billion

Catalent Announces Pricing Of Public Offering Of Common Stock

Catalent Announces Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Catalent Inc

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Industry

Biotechnology & Drugs

Contact Info

14 Schoolhouse Rd

SOMERSET, NJ

08873-1213

United States

+1.732.5376200

https://www.catalent.com/

Executive Leadership

John R. Chiminski

Chairman of the Board, Chief Executive Officer

Alessandro Maselli

President, Chief Operating Officer

Wetteny Joseph

Chief Financial Officer, Senior Vice President

Jonathan Arnold

President - Oral Drug Delivery Solutions

Manja Boerman

President - Cell & Gene Therapy

Key Stats

1.77 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.1K

2018

2.5K

2019

2.5K

2020(E)

3.0K
EPS (USD)

2017

1.460

2018

1.750

2019

1.920

2020(E)

1.972
Price To Earnings (TTM)
114.30
Price To Sales (TTM)
4.81
Price To Book (MRQ)
6.01
Price To Cash Flow (TTM)
39.28
Total Debt To Equity (MRQ)
114.47
LT Debt To Equity (MRQ)
104.75
Return on Investment (TTM)
2.72
Return on Equity (TTM)
2.38

Latest News

Latest News

Moderna eyes third quarter for first doses of potential COVID-19 vaccine with Catalent deal

Moderna Inc <MRNA.O> said on Thursday it was partnering with contract drugmaker Catalent Inc <CTLT.N> to prepare an initial 100 million doses of its coronavirus vaccine for the United States, starting in the third quarter of this year.

BRIEF-Moderna And Catalent Announce Manufacturing Collaboration Of Moderna’S Covid-19 Vaccine Candidate

* MODERNA AND CATALENT ANNOUNCE COLLABORATION FOR FILL-FINISH MANUFACTURING OF MODERNA’S COVID-19 VACCINE CANDIDATE

Moderna names Catalent as manufacturing partner for potential COVID-19 vaccine

Moderna Inc said on Thursday it has partnered with contract drugmaker Catalent Inc to produce 100 million doses of its experimental COVID-19 vaccine starting in the third quarter of 2020.

BRIEF-Viralclear Partners With Catalent On Potential Treatment For COVID-19

* VIRALCLEAR PARTNERS WITH CATALENT ON POTENTIAL TREATMENT FOR COVID-19

AstraZeneca picks Catalent for packaging, supplying potential COVID-19 vaccine

British drugmaker AstraZeneca Plc has struck a deal with contract manufacturer Catalent Inc to help meet its global target of supplying two billion doses of its potential COVID-19 vaccine.

UPDATE 1-AstraZeneca picks Catalent for packaging, supplying potential COVID-19 vaccine

British drugmaker AstraZeneca Plc has struck a deal with contract manufacturer Catalent Inc to help meet its global target of supplying two billion doses of its potential COVID-19 vaccine.

BRIEF-Catalent Signs Deal With Astrazeneca To Manufacture Covid-19 Vaccine Candidate

* CATALENT SIGNS AGREEMENT WITH ASTRAZENECA TO MANUFACTURE COVID-19 VACCINE CANDIDATE

AstraZeneca picks Catalent for packaging potential COVID-19 vaccine

AstraZeneca Plc has struck a deal with Catalent Inc for packaging its potential COVID-19 vaccine, as the British drugmaker prepares to meet its global target of making two billion doses of the vaccine.

BRIEF-Catalent Announces Pricing Of Public Offering Of Common Stock

* CATALENT, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalent Announces Public Offering Of Common Stock

* CATALENT INC - LAUNCHED UNDERWRITTEN PUBLIC OFFERING OF $550 MILLION OF COMMON STOCK

BRIEF-Catalent Signs Agreement With Johnson & Johnson To Be U.S. Manufacturing Partner For Lead Covid-19 Vaccine Candidate

* CATALENT SIGNS AGREEMENT WITH JOHNSON & JOHNSON TO BE U.S. MANUFACTURING PARTNER FOR LEAD COVID-19 VACCINE CANDIDATE

BRIEF-Perrigo And Catalent Announce FDA Approval Of Perrigo's AB-Rated Generic Version Of Proair HFA

* PERRIGO AND CATALENT ANNOUNCE FDA APPROVAL OF PERRIGO'S AB-RATED GENERIC VERSION OF PROAIR® HFA

BRIEF-Catalent Announces Upsizing And Pricing Of Private Offering Of Senior Unsecured Notes Due 2028

* CATALENT ANNOUNCES UPSIZING AND PRICING OF PRIVATE OFFERING OF SENIOR UNSECURED NOTES DUE 2028

BRIEF-Catalent Announces Private Offering Of €450 Million Of Senior Unsecured Notes Due 2028

* CATALENT ANNOUNCES LAUNCH OF PRIVATE OFFERING OF €450 MILLION OF SENIOR UNSECURED NOTES DUE 2028 Source text for Eikon: Further company coverage:

IFR US ECM Weekly Wrap-up

WEEKLY TOTAL $11.2bn – IPO $3.1bn – ABB/BLOCK $1.2bn – FOLLOW-ON $6.1bn – CB $825m Monday

IFR US ECM Calendar

Catalent (US, CRO) – $500m Block. 8.45m shares (100% prim) at $59.20 versus $59.20-$59.80 marketing and $61.65 last sale. JPM, UBS.

IFR US ECM Calendar

Catalent (US, CRO) – $500m Block. 8.45m shares (100% prim) at $59.20 versus $59.20-$59.80 marketing and $61.65 last sale. JPM, UBS. Final share count TBC.

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

Catalent to buy Paragon Bioservices for $1.2 bln

Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion.

Catalent to buy Paragon Bioservices for $1.2 billion - WSJ

Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up